ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

5/2/25 8:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ALXO alert in real time by email

SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced plans to report its first quarter 2025 financial results on Thursday, May 8th, 2025, before market open.

The company will not be hosting a teleconference in conjunction with its financial results press release.

About ALX Oncology

ALX Oncology (NASDAQ:ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives. ALX Oncology's lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology's second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action and is anticipated to enter Phase 1 trials mid-2025. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.

Investor Relations Contact:

Elhan Webb, CFA, IR Consultant

[email protected]

Media Contact:

Audra Friis, Sam Brown, Inc.

[email protected]

(917) 519-9577

Get the next $ALXO alert in real time by email

Recent Analyst Ratings for

$ALXO

Date	Price Target	Rating	Analyst
3/6/2025	$2.00 → $3.00	Hold → Buy	Jefferies
12/19/2024	$12.00 → $2.00	Buy → Hold	Jefferies
3/8/2024	$10.00 → $14.00	Buy → Hold	Stifel
12/8/2023	$8.00 → $18.00	Hold → Buy	Jefferies
3/1/2022	$60.00 → $36.00	Buy	Stifel
12/22/2021	$65.00 → $25.00	Buy → Hold	Jefferies
9/30/2021	$106.00	Buy	Stifel

More analyst ratings

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

Chat with this insight

Recent Analyst Ratings for $ALXO

$ALXO Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Hemrajani Rekha bought $46,404 worth of shares (30,000 units at $1.55), increasing direct ownership by 1,000% to 33,000 units (SEC Form 4)

Amendment: CHIEF FINANCIAL OFFICER Garcia Peter S bought $102,338 worth of shares (12,000 units at $8.53), increasing direct ownership by 11% to 122,348 units (SEC Form 4)

CHIEF FINANCIAL OFFICER Garcia Peter S bought $102,338 worth of shares (12,000 units at $8.53), increasing direct ownership by 11% to 122,348 units (SEC Form 4)

$ALXO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by SVP, FINANCE AND CAO Pinto Shelly

SEC Form 4 filed by Chief Medical Officer Sandler Alan B.

SEC Form 4 filed by Chief Financial Officer Shantharam Harish

$ALXO Press Releases

Fastest customizable press release news feed in the world

ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference

ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event

ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

$ALXO Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

ALX Oncology upgraded by Jefferies with a new price target

ALX Oncology downgraded by Jefferies with a new price target

ALX Oncology downgraded by Stifel with a new price target

$ALXO Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

$ALXO Leadership Updates

Live Leadership Updates

ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors

ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer

ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

$ALXO Financials

Live finance-specific insights

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

$ALXO SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by ALX Oncology Holdings Inc.

Amendment: SEC Form SCHEDULE 13G/A filed by ALX Oncology Holdings Inc.

SEC Form 10-Q filed by ALX Oncology Holdings Inc.

Recent Analyst Ratings for
$ALXO

$ALXO
Insider Purchases

$ALXO
Insider Trading

$ALXO
Press Releases

$ALXO
Analyst Ratings

$ALXO
Large Ownership Changes

$ALXO
Leadership Updates

$ALXO
Financials

$ALXO
SEC Filings